NCT00003525View on ClinicalTrials.gov

Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 3, 1996

Primary Completion Date

January 22, 1998

Study Completion Date

January 22, 1998

Conditions
Cervical Cancer Stage IVVulvar Cancer, Stage IV
Interventions
DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER